miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers
Purpose In this study, miR-542-3p appended SRF/ATRA-loaded solid lipid nanoparticle was successfully prepared and demonstrated for its therapeutic efficacy against gastric cancers. Methods The particles were nanosized and typically spherical in shape. In vitro release study showed that release of AT...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical research 2017-12, Vol.34 (12), p.2710-2719 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2719 |
|---|---|
| container_issue | 12 |
| container_start_page | 2710 |
| container_title | Pharmaceutical research |
| container_volume | 34 |
| creator | Li, Tong Zhang, Yu Meng, Yuan-Pu Bo, Li-Shan Ke, Wen-Bo |
| description | Purpose
In this study, miR-542-3p appended SRF/ATRA-loaded solid lipid nanoparticle was successfully prepared and demonstrated for its therapeutic efficacy against gastric cancers.
Methods
The particles were nanosized and typically spherical in shape.
In vitro
release study showed that release of ATRA was significantly slower compared to that of SRF from the NPs.
Results
MTT assay showed that miR-542-3p have a strong inhibitory effect on the proliferation of MGC-803 cancer cells in a typical dose dependent manner. Nanocarrier encapsulation of SRF + ATRA induced a significantly higher cytotoxic effect compared to either individual drug or cocktail combinations indicating that the cellular uptake of different formulations was rate limiting factor in the therapeutic efficacy. Importantly, miR-542-3p-based miSRNP exhibited an extremely significant toxic effect compared to any other treated group. Importantly, miSRNP induced a significantly higher early (~55%) and late (~15%) apoptotic effect in gastric cancer cells.
In vivo
anticancer analysis results clearly suggest that nanoparticle encapsulation of combination of SRF and miRNA (with miRNA) will have greater antitumor efficacy in tumor mice.
Conclusion
Overall, unique combination of miRNA coupled with SRF + ATRA in a lipid nanocarrier could be a promising therapeutic approach in gastric cancer treatment. |
| doi_str_mv | 10.1007/s11095-017-2202-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1968662399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747438771</galeid><sourcerecordid>A747438771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3547-d324073cc4ccf2498547bd8e0d8c6fb4091e883add0bf25c3c22989841badf6c3</originalsourceid><addsrcrecordid>eNp1kctu1DAYhS0EokPhAdggS2zKwq1vie1lNBpKpRFIQ5HYWY4vravECXZm0YfgnfEwLRcJ5IXt83_n9-UA8Jrgc4KxuCiEYNUgTASiFFMknoAVaQRDCvOvT8EKC8qRFJycgBel3GGMJVH8OTihikjSSrEC38e4Qw2niM2wm2efnHfw85RN8Cn2F90woCWbVODOLzFN0cLORgfPuutd9w5tJ3Pgt3Gu2keTptnkJdrBF7hMcJNuTbIeLrcedqnqh12GmxDq0t7DmOClKUuuTdc_S-UleBbMUPyrh_kUfHm_uV5_QNtPl1frbossa7hAjlGOBbOWWxsoV7KKvZMeO2nb0HOsiJeSGedwH2hjmaVUSSU56Y0LrWWn4O2x75ynb3tfFn037XOqR2qiWtm2lCn1m7oxg9cxhal-hR1jsboTXHAmhSCVOv8HVYfzY7RT8iFW_S8DORpsnkrJPug5x9Hke02wPuSqj7nqmqs-5KpF9bx5uPC-H7375XgMsgL0CJRaSjc-__Gi_3b9Advcquo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1968662399</pqid></control><display><type>article</type><title>miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers</title><source>SpringerLink Journals</source><creator>Li, Tong ; Zhang, Yu ; Meng, Yuan-Pu ; Bo, Li-Shan ; Ke, Wen-Bo</creator><creatorcontrib>Li, Tong ; Zhang, Yu ; Meng, Yuan-Pu ; Bo, Li-Shan ; Ke, Wen-Bo</creatorcontrib><description>Purpose
In this study, miR-542-3p appended SRF/ATRA-loaded solid lipid nanoparticle was successfully prepared and demonstrated for its therapeutic efficacy against gastric cancers.
Methods
The particles were nanosized and typically spherical in shape.
In vitro
release study showed that release of ATRA was significantly slower compared to that of SRF from the NPs.
Results
MTT assay showed that miR-542-3p have a strong inhibitory effect on the proliferation of MGC-803 cancer cells in a typical dose dependent manner. Nanocarrier encapsulation of SRF + ATRA induced a significantly higher cytotoxic effect compared to either individual drug or cocktail combinations indicating that the cellular uptake of different formulations was rate limiting factor in the therapeutic efficacy. Importantly, miR-542-3p-based miSRNP exhibited an extremely significant toxic effect compared to any other treated group. Importantly, miSRNP induced a significantly higher early (~55%) and late (~15%) apoptotic effect in gastric cancer cells.
In vivo
anticancer analysis results clearly suggest that nanoparticle encapsulation of combination of SRF and miRNA (with miRNA) will have greater antitumor efficacy in tumor mice.
Conclusion
Overall, unique combination of miRNA coupled with SRF + ATRA in a lipid nanocarrier could be a promising therapeutic approach in gastric cancer treatment.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-017-2202-7</identifier><identifier>PMID: 29181687</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antitumor activity ; Apoptosis ; Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Cancer ; Care and treatment ; Cell proliferation ; Comparative analysis ; Cytotoxicity ; Encapsulation ; Formulations ; Gastric cancer ; Health aspects ; Inhibitor drugs ; Lipids ; Medical Law ; MicroRNA ; miRNA ; Nanoparticles ; Pharmacology/Toxicology ; Pharmacy ; Research Paper ; Retinoic acid ; Stomach cancer ; Targeted cancer therapy</subject><ispartof>Pharmaceutical research, 2017-12, Vol.34 (12), p.2710-2719</ispartof><rights>Springer Science+Business Media, LLC 2017</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Pharmaceutical Research is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3547-d324073cc4ccf2498547bd8e0d8c6fb4091e883add0bf25c3c22989841badf6c3</citedby><cites>FETCH-LOGICAL-c3547-d324073cc4ccf2498547bd8e0d8c6fb4091e883add0bf25c3c22989841badf6c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11095-017-2202-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11095-017-2202-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29181687$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Tong</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Meng, Yuan-Pu</creatorcontrib><creatorcontrib>Bo, Li-Shan</creatorcontrib><creatorcontrib>Ke, Wen-Bo</creatorcontrib><title>miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>Purpose
In this study, miR-542-3p appended SRF/ATRA-loaded solid lipid nanoparticle was successfully prepared and demonstrated for its therapeutic efficacy against gastric cancers.
Methods
The particles were nanosized and typically spherical in shape.
In vitro
release study showed that release of ATRA was significantly slower compared to that of SRF from the NPs.
Results
MTT assay showed that miR-542-3p have a strong inhibitory effect on the proliferation of MGC-803 cancer cells in a typical dose dependent manner. Nanocarrier encapsulation of SRF + ATRA induced a significantly higher cytotoxic effect compared to either individual drug or cocktail combinations indicating that the cellular uptake of different formulations was rate limiting factor in the therapeutic efficacy. Importantly, miR-542-3p-based miSRNP exhibited an extremely significant toxic effect compared to any other treated group. Importantly, miSRNP induced a significantly higher early (~55%) and late (~15%) apoptotic effect in gastric cancer cells.
In vivo
anticancer analysis results clearly suggest that nanoparticle encapsulation of combination of SRF and miRNA (with miRNA) will have greater antitumor efficacy in tumor mice.
Conclusion
Overall, unique combination of miRNA coupled with SRF + ATRA in a lipid nanocarrier could be a promising therapeutic approach in gastric cancer treatment.</description><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell proliferation</subject><subject>Comparative analysis</subject><subject>Cytotoxicity</subject><subject>Encapsulation</subject><subject>Formulations</subject><subject>Gastric cancer</subject><subject>Health aspects</subject><subject>Inhibitor drugs</subject><subject>Lipids</subject><subject>Medical Law</subject><subject>MicroRNA</subject><subject>miRNA</subject><subject>Nanoparticles</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Research Paper</subject><subject>Retinoic acid</subject><subject>Stomach cancer</subject><subject>Targeted cancer therapy</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kctu1DAYhS0EokPhAdggS2zKwq1vie1lNBpKpRFIQ5HYWY4vravECXZm0YfgnfEwLRcJ5IXt83_n9-UA8Jrgc4KxuCiEYNUgTASiFFMknoAVaQRDCvOvT8EKC8qRFJycgBel3GGMJVH8OTihikjSSrEC38e4Qw2niM2wm2efnHfw85RN8Cn2F90woCWbVODOLzFN0cLORgfPuutd9w5tJ3Pgt3Gu2keTptnkJdrBF7hMcJNuTbIeLrcedqnqh12GmxDq0t7DmOClKUuuTdc_S-UleBbMUPyrh_kUfHm_uV5_QNtPl1frbossa7hAjlGOBbOWWxsoV7KKvZMeO2nb0HOsiJeSGedwH2hjmaVUSSU56Y0LrWWn4O2x75ynb3tfFn037XOqR2qiWtm2lCn1m7oxg9cxhal-hR1jsboTXHAmhSCVOv8HVYfzY7RT8iFW_S8DORpsnkrJPug5x9Hke02wPuSqj7nqmqs-5KpF9bx5uPC-H7375XgMsgL0CJRaSjc-__Gi_3b9Advcquo</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Li, Tong</creator><creator>Zhang, Yu</creator><creator>Meng, Yuan-Pu</creator><creator>Bo, Li-Shan</creator><creator>Ke, Wen-Bo</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20171201</creationdate><title>miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers</title><author>Li, Tong ; Zhang, Yu ; Meng, Yuan-Pu ; Bo, Li-Shan ; Ke, Wen-Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3547-d324073cc4ccf2498547bd8e0d8c6fb4091e883add0bf25c3c22989841badf6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell proliferation</topic><topic>Comparative analysis</topic><topic>Cytotoxicity</topic><topic>Encapsulation</topic><topic>Formulations</topic><topic>Gastric cancer</topic><topic>Health aspects</topic><topic>Inhibitor drugs</topic><topic>Lipids</topic><topic>Medical Law</topic><topic>MicroRNA</topic><topic>miRNA</topic><topic>Nanoparticles</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Research Paper</topic><topic>Retinoic acid</topic><topic>Stomach cancer</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Tong</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Meng, Yuan-Pu</creatorcontrib><creatorcontrib>Bo, Li-Shan</creatorcontrib><creatorcontrib>Ke, Wen-Bo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Tong</au><au>Zhang, Yu</au><au>Meng, Yuan-Pu</au><au>Bo, Li-Shan</au><au>Ke, Wen-Bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>34</volume><issue>12</issue><spage>2710</spage><epage>2719</epage><pages>2710-2719</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><abstract>Purpose
In this study, miR-542-3p appended SRF/ATRA-loaded solid lipid nanoparticle was successfully prepared and demonstrated for its therapeutic efficacy against gastric cancers.
Methods
The particles were nanosized and typically spherical in shape.
In vitro
release study showed that release of ATRA was significantly slower compared to that of SRF from the NPs.
Results
MTT assay showed that miR-542-3p have a strong inhibitory effect on the proliferation of MGC-803 cancer cells in a typical dose dependent manner. Nanocarrier encapsulation of SRF + ATRA induced a significantly higher cytotoxic effect compared to either individual drug or cocktail combinations indicating that the cellular uptake of different formulations was rate limiting factor in the therapeutic efficacy. Importantly, miR-542-3p-based miSRNP exhibited an extremely significant toxic effect compared to any other treated group. Importantly, miSRNP induced a significantly higher early (~55%) and late (~15%) apoptotic effect in gastric cancer cells.
In vivo
anticancer analysis results clearly suggest that nanoparticle encapsulation of combination of SRF and miRNA (with miRNA) will have greater antitumor efficacy in tumor mice.
Conclusion
Overall, unique combination of miRNA coupled with SRF + ATRA in a lipid nanocarrier could be a promising therapeutic approach in gastric cancer treatment.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29181687</pmid><doi>10.1007/s11095-017-2202-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2017-12, Vol.34 (12), p.2710-2719 |
| issn | 0724-8741 1573-904X |
| language | eng |
| recordid | cdi_proquest_journals_1968662399 |
| source | SpringerLink Journals |
| subjects | Antitumor activity Apoptosis Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Cancer Care and treatment Cell proliferation Comparative analysis Cytotoxicity Encapsulation Formulations Gastric cancer Health aspects Inhibitor drugs Lipids Medical Law MicroRNA miRNA Nanoparticles Pharmacology/Toxicology Pharmacy Research Paper Retinoic acid Stomach cancer Targeted cancer therapy |
| title | miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A32%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-542-3p%20Appended%20Sorafenib/All-trans%20Retinoic%20Acid%20(ATRA)-Loaded%20Lipid%20Nanoparticles%20to%20Enhance%20the%20Anticancer%20Efficacy%20in%20Gastric%20Cancers&rft.jtitle=Pharmaceutical%20research&rft.au=Li,%20Tong&rft.date=2017-12-01&rft.volume=34&rft.issue=12&rft.spage=2710&rft.epage=2719&rft.pages=2710-2719&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-017-2202-7&rft_dat=%3Cgale_proqu%3EA747438771%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1968662399&rft_id=info:pmid/29181687&rft_galeid=A747438771&rfr_iscdi=true |